Hard decisions at Bard as it aims for an annual $43m gain from restructuring exercise
This article was originally published in Clinica
Executive Summary
Restructuring charges of $44.1 million in the third quarter turned a profit into a loss for CR Bard. Over the next 24 months, seven of its 28 manufacturing plants around the world will be closed.